{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:19Z","timestamp":1793575039467,"version":"4.5.0"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-na\u00efve or had inadequate response\/intolerance to tumor necrosis factor inhibitors (TNFi-IR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      BE OPTIMAL (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03895203\">NCT03895203<\/jats:ext-link>\n                      ; bDMARD-na\u00efve patients) and BE COMPLETE (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03896581\">NCT03896581<\/jats:ext-link>\n                      ; TNFi-IR patients) are phase III studies of subcutaneous bimekizumab 160 mg every 4 weeks. Both studies were double-blind and placebo-controlled to 16 weeks. Patients who completed week 52 of BE OPTIMAL or week 16 of BE COMPLETE were eligible for the open-label extension, BE VITAL (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04009499\">NCT04009499<\/jats:ext-link>\n                      ), during which all patients received bimekizumab. Patient-reported pain, fatigue, physical function, HRQOL, and work productivity are reported to week 52 or 40 (52\/40) using individual study data for bimekizumab and placebo treatment arms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bimekizumab-randomized patients demonstrated sustained mean improvements from baseline in patient-reported outcomes to week 52\/40, including pain (visual analog scale [0-100 mm]: bDMARD-na\u00efve \u221230.5; TNFi-IR \u221231.8), fatigue (Functional Assessment of Chronic Illness Therapy\u2013Fatigue scale [0-52]: bDMARD-na\u00efve 5.3; TNFi-IR 6.0), physical function (Health Assessment Questionnaire\u2013Disability Index [0-3]: bDMARD-na\u00efve \u22120.34; TNFi-IR \u22120.39), and HRQOL (36-item Short Form Health Survey, physical component summary: bDMARD-na\u00efve 8.1; TNFi-IR 8.4); placebo patients who switched to bimekizumab at week 16 demonstrated comparable levels of improvement from week 16 to week 52\/40. Improvements in overall work impairment were sustained among bimekizumab-randomized patients to week 52. Similar trends were observed for absenteeism, presenteeism, and activity impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-na\u00efve and TNFi-IR patients with active PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-0923","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T08:25:30Z","timestamp":1738398330000},"page":"466-478","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-4205","authenticated-orcid":false,"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Bajracharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Coarse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Lyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"2026012716550922000_52.5.466.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"2026012716550922000_52.5.466.2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001321"},{"key":"2026012716550922000_52.5.466.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"2026012716550922000_52.5.466.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2026012716550922000_52.5.466.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker216"},{"key":"2026012716550922000_52.5.466.6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221140846"},{"key":"2026012716550922000_52.5.466.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935"},{"key":"2026012716550922000_52.5.466.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160904"},{"key":"2026012716550922000_52.5.466.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2026012716550922000_52.5.466.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00443-y"},{"key":"2026012716550922000_52.5.466.11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026012716550922000_52.5.466.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855"},{"key":"2026012716550922000_52.5.466.13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004464"},{"key":"2026012716550922000_52.5.466.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"2026012716550922000_52.5.466.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"2026012716550922000_52.5.466.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2026012716550922000_52.5.466.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"2026012716550922000_52.5.466.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026012716550922000_52.5.466.19","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0094-5"},{"key":"2026012716550922000_52.5.466.20","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"2026012716550922000_52.5.466.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"2026012716550922000_52.5.466.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0284-8"},{"key":"2026012716550922000_52.5.466.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae277"},{"key":"2026012716550922000_52.5.466.24","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24242"},{"key":"2026012716550922000_52.5.466.25","unstructured":"Maruish ME , editor. User\u2019s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: Quality Metric Incorporated; 2011."},{"key":"2026012716550922000_52.5.466.26","unstructured":"EuroQol Research Foundation 2021 . EQ-5D-3L user guide. [Internet. Accessed January 30, 2025.] Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-3LUserguide-23-07.pdf"},{"key":"2026012716550922000_52.5.466.27","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"2026012716550922000_52.5.466.28","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0155-5"},{"key":"2026012716550922000_52.5.466.29","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"2026012716550922000_52.5.466.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"2026012716550922000_52.5.466.31","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15237"},{"key":"2026012716550922000_52.5.466.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210579"},{"key":"2026012716550922000_52.5.466.33","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000204257.25875.04"},{"key":"2026012716550922000_52.5.466.34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004202"},{"key":"2026012716550922000_52.5.466.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171034"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:55:43Z","timestamp":1769561743000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.3899\/jrheum.2024-0923"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0923","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}